Is There a Substitute for Mounjaro? What Your Options Actually Are

What makes Mounjaro distinct from other weight-loss medicines?

Mounjaro (tirzepatide) activates two gut-hormone receptors simultaneously, GLP-1 and GIP. Every other licensed weight-loss medicine in the UK targets GLP-1 alone. That dual action is why the clinical trial results look different: in the SURMOUNT-1 trial, participants at the 15mg dose lost an average of around 20–21% of body weight over 72 weeks, a figure that held up in the NICE appraisal of tirzepatide (TA1026). So when someone asks whether there is a substitute for Mounjaro, the honest answer is: there are alternatives, but nothing currently licensed in the UK shares its exact mechanism.

That matters for the decision. If you are considering switching because of availability, cost, or tolerability, the substitute will behave differently in your body, and a prescriber needs to factor that in. You can explore what Mounjaro is and how it works in more detail if you are starting from scratch.

Wegovy injection: the most direct comparison

Wegovy (semaglutide 2.4mg weekly injection, made by Novo Nordisk) is a GLP-1 receptor agonist and the alternative most often discussed alongside Mounjaro. The STEP 1 trial reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, as detailed in the NHS semaglutide medicines page. A newer 7.2mg maintenance dose was approved by the MHRA in January 2026 and a dedicated single-dose pen followed in April 2026, with trials reporting around 20.7% average loss, closing the gap with tirzepatide's headline figures.

The side-effect profile is broadly similar: nausea, constipation, and other gastrointestinal effects are most common, particularly in the first weeks after starting or increasing the dose. One practical difference worth knowing: women on oral contraceptives using tirzepatide are advised to add a non-oral method for the first four weeks of treatment and after each dose increase, because absorption of the pill can be reduced. That concern does not currently apply to semaglutide in the same way. For a direct breakdown of the two medicines, the comparison of Mounjaro alternatives for weight loss goes deeper on the numbers.

The Wegovy tablet and orlistat: two very different substitutes

For people who want to avoid injections entirely, there are now two oral options, though they are worlds apart in how they work.

The Wegovy tablet (oral semaglutide, approved by the MHRA on 11 June 2026) escalates from 1.5mg to a 25mg daily maintenance dose. You take it first thing in the morning on an empty stomach, with a small amount of plain water, and wait at least 30 minutes before eating, drinking coffee, or taking other medicines. Keep it in a bag or on the kitchen counter rather than the fridge, no cold-chain storage is needed, which makes it the most practical option for travel. The OASIS 4 phase-3 trial reported an average weight reduction of around 13.6% over 64 weeks versus placebo. Among participants who stayed fully adherent to treatment, that figure rose to around 17%.

Orlistat is a capsule that blocks absorption of roughly a third of the fat you eat. It has no effect on appetite signalling. Results are more modest than GLP-1 medicines, and it carries a specific dietary requirement: keeping fat intake low at each meal or you can expect significant gastrointestinal discomfort. It remains a legitimate licensed option for some people, particularly where injections or GLP-1 medicines are not suitable. The NHS orlistat medicines page sets out full prescribing details.

The cost question, and what to do next

Price is often what prompts the search for a substitute. Eli Lilly raised Mounjaro's UK list price from September 2025, with typical private prices now ranging roughly £149–£375 per month depending on dose and provider. If cost is the driver, it is worth reading a clear Mounjaro price comparison for the UK before drawing conclusions, headline prices often exclude consultation fees, prescription charges, and delivery, so the real comparison is rarely what it looks like at first glance.

There are also medicines in late-stage trials (retatrutide is one discussed frequently) that are not yet licensed anywhere for weight management. If you have read about whether retatrutide might outperform Mounjaro, the short answer is that it remains investigational; it is not a substitute available today. The same applies to orforglipron, covered in our orforglipron versus tirzepatide page.

There is no generic tirzepatide available in the UK, and the picture on that is unlikely to change soon, the timeline for a Mounjaro generic explains why. If you are ready to talk through which licensed option fits your circumstances, a prescriber at nume will review your consultation the same day, a real clinician, not automated software. Start your free consultation and we will take it from there.